We are joined by Othman Al-Sawaf at EHA 2019 to discuss his presentation on high efficacy of venetoclax plus obinutuzumab in patients with complex karyotype (CKT) and chronic lymphocytic leukemia (CLL): A prospective analysis from the CLL14 trial.
1. Could you tell us a little about complex karyotype (CKT) in chronic lymphocytic leukemia (CLL) and its impact on prognosis? (0:05)
2. What are the limitations of current therapeutic options for CLL CKT patients? (1:13)
3. What is the rationale for the use of venetoclax plus obinutuzumab in this treatment setting? (2:00)
4. What were the efficacy and safety findings of your recent analysis of the CLL14 trial? (3:15)
5. Which patients are most likely to respond to this combination and in which patients is it contraindicated? (4:15)
Othman Al-Sawaf has no conflicts of interest to declare in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Leukaemia
Michael Mauro, ASH 2021: 48-Week Update of the Phase III ASCEMBL Trial
Professor Michael Mauro (Memorial Sloan Kettering Cancer Center, New York City, NY, USA) discusses the 48-week update from the ASCEMBL trial, a multicenter, open-label, phase III study of the efficacy and safety of asciminib, a first-in-class STAMP inhibitor, vs Bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: […]
Robin Foà: Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) discusses his recent phase II study exploring the benefits, efficacy and safety of tyrosine kinase inhibitors dasatinib–blinatumomab for the treatment of Ph-positive acute lymphoblastic leukemia in adults. Questions What is the rationale for the use of dasatinib plus glucocorticoids, followed by blinatumomab, rather […]
Elias Jabbour, ASH 2021: Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (PACE and OPTIC Trials)
We were delighted to catch up with editorial board member Prof Elias Jabbour (MD Anderson Cancer Center, Houston, TX, USA) to discuss his presentation at the American Society of Hematology (ASH) Annual Meeting on dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia from the PACE and Optic trials. Questions 1. What […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!